0001209191-20-049430.txt : 20200903 0001209191-20-049430.hdr.sgml : 20200903 20200903164644 ACCESSION NUMBER: 0001209191-20-049430 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TOMSICEK MICHAEL JOHN CENTRAL INDEX KEY: 0001570392 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 201159708 MAIL ADDRESS: STREET 1: 28 OVERLOOK DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-01 0 0001674416 CRISPR Therapeutics AG CRSP 0001570392 TOMSICEK MICHAEL JOHN C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Common Shares 2020-09-01 4 M 0 12000 17.75 A 12410 D Common Shares 2020-09-01 4 S 0 2800 91.39 D 9610 D Common Shares 2020-09-01 4 S 0 6400 92.23 D 3210 D Common Shares 2020-09-01 4 S 0 2800 93.18 D 410 D Stock Option (Right to Buy) 17.75 2020-09-01 4 M 0 12000 0.00 D 2027-11-21 Common Shares 12000 156000 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.78 to $91.76, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.80 to $92.72, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.82 to $93.74, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month. /s/ Michael Esposito, attorney-in-fact 2020-09-03